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ABSTRACT
Although the use of aspirin has substantially reduced the risks of cardiovascular events and death, its
potential mechanisms have not been fully elucidated. In a previous study, we found that aspirin triggers
cellular autophagy. In the present study, we aimed to determine the protective effects of aspirin on human
coronary artery endothelial cells (HCAECs) and explore its underlying mechanisms. HCAECs were treated
with oxidized low-density lipoprotein (ox-LDL), angiotensin II (Ang-II), or high glucose (HG) with or
without aspirin stimulation. The expression levels of endothelial nitric oxide (NO) synthase (eNOS),
p-eNOS, LC3, p62, phosphor-nuclear factor kappa B (p-NF-kB), p-p38 mitogen-activated protein kinase
(p-p38 MAPK), and Beclin-1 were detected via immunoblotting analysis. Concentrations of soluble
intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1)
were measured via ELISA. NO levels were determined using the Griess reagent. Autophagic flux was
tracked by tandem mRFP-GFP-tagged LC3. Results showed that aspirin increased eNOS level and reduced
injury to the endothelial cells (ECs) caused by ox-LDL, Ang-II, and HG treatment in a dose-dependent
manner. Aspirin also increased the LC3II/LC3I ratio, decreased p62 expression, and enhanced autophagic
flux (autophagosome and autolysosome puncta) in the HCAECs. p-NF-kB and p-p38 mitogen-activated
protein kinase inhibition, sVCAM-1 and sICAM-1 secretion, and eNOS activity promotion by aspirin
treatment were found to be dependent on Beclin-1. These results suggested that aspirin can protect ECs
from ox-LDL-, Ang-II-, and HG-induced injury by activating autophagy in a Beclin-1-dependent manner.
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INTRODUCTION
Atherosclerosis is the main pathology of coronary artery diseases. Endothelial cell (EC)
dysfunction is the initial stage of atherosclerosis. EC functions play a vital role in maintaining
vascular homeostasis, blood flow and pressure control, and balancing insurance of anticoagulant
and antithrombotic properties [1]. Protection and enhancement of EC functions are beneficial
for the prevention and treatment of coronary artery diseases. Oxidized low-density lipoprotein
(ox-LDL) has a vital role in atherosclerosis development [2]. ox-LDL decreases EC proliferation,
migration, and tube formation, which are processes that might be associated with nuclear factor
kappa B (NF-kB) p65 activation and vascular endothelial growth factor downregulation [3]. ox-
LDL also promotes foam cell formation, which exerts a chemical toxicity effect on smooth
muscle cells to accelerate smooth muscle cell migration. Angiotensin II (Ang-II) induces in-
flammatory responses and leads to hypertension and coronary artery diseases by activating NF-
kB [4]. High glucose (HG) also induces endothelial dysfunction, but the underlying mechanism
has not been fully elucidated. Production of different cytokines in ECs has been found impaired
under HG conditions [5].
Aspirin, which is widely used in medicine, remarkably reduces the risks of cardiovascular
events and death. Aspirin has excellent antiplatelet functions and powerful vascular endothelial
protection effects [6–10]. The mechanisms by which aspirin protects EC functions have been
investigated. Aspirin can promote nitric oxide (NO) levels by directly stimulating the endothelial
NO synthase (eNOS) [11]. Aspirin can exert protective effects on ox-LDL-induced endothelial
injury by inhibiting cyclooxygenase-2 and intercellular adhesion molecule-1 (ICAM-1)
expression [12]. Aspirin also protects against Ang-II-induced end organ damage by inhibiting
NF-kB [4]. Furthermore, aspirin alters HG-induced changes in cellular Ca2þ homeostasis and
NO production involving the reduction of O2 levels [11].
Autophagy is a life phenomenon in eukaryotic cells that plays a valuable role in metabolism.
The LC3 II/I ratio is used as an indicator of autophagy–mitophagy flux. The p62 protein, which
is also called SQSTM1, SQSTM1/p62 binds the autophagosome membrane protein LC3/Atg8,
thereby transporting a protein polymer containing SQSTM1/p62 to the autophagosome. In
autophagy, autophagosome degradation by lysosomes decreases SQSTM1/p62 levels.
Mammalian Beclin-1, which is an ortholog of the Atg6/vacuolar protein sorting (Vps)-30
protein in yeast, participates in the autophagic process. The Beclin-1–Vps34 complex facilitates
lipid membrane extension, cargo recruitment, and autophagosome maturation [13, 14]. Auto-
phagosomes and autophagic lysosome formation are markers of autophagy in cells [15].
Available evidence suggests that aspirin works effectively in the primary prevention of various
tumors, such as colon, breast, lung, and prostate tumors [16], and its mechanisms have
generated interest among researchers. Aspirin features an autophagic effect on colorectal cancer
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cells by inhibiting the mammalian target of rapamycin (mTOR) signaling and activating the
adenosine 50-monophosphate-activated protein (AMPK) pathway [17]. In a previous study, we
found that aspirin reduces the incidence of hepatocellular carcinoma (HCC) and plays a syn-
ergistic role with chemotherapy for HCC treatment that might be related to induced autophagy
[18].
However, the relationship between autophagy induction and vascular endothelial protection
by aspirin has not been elucidated yet [6–10]. In the present study, we aimed to determine
whether aspirin can protect human coronary artery ECs (HCAECs) by inducing autophagy
under different injury conditions (ox-LDL, Ang-II, and HG) and explore its underlying
mechanisms.
MATERIALS AND METHODS
Cell culture and treatment
HCAECs were purchased from Cell Applications, Inc. (San Diego, CA, USA). The HCAECs
were maintained at 37 8C in a humidified mixture of 95% air and 5% CO2 in EBM-2 medium
(Cat. No. CC3162; Lonza, USA) with endothelial growth medium supplement mix (hFGF,
VEGF, IGF-1, hEGF, hydrocortisone, heparin, and GA-1000) supplemented with 5% fetal
bovine serum and 1% penicillin–streptomycin (Gibco, USA). Cells between four and six pas-
sages were used in all experiments. The cells were treated with or without aspirin in a dose-
dependent manner (0.315, 0.63, 1.25, 2.5, and 5 mM) (Sangon Biotech, Shanghai, China) for 16
h. Alternatively, the cells were stimulated using 50 mg/mL ox-LDL (Yiyuan Biotechnology,
China), 1 mM Ang-II (Sigma-Aldrich, USA), and 25 mM HG (Sigma-Aldrich, USA) for 30 min,
and then aspirin (2.5 mM) was used to stimulate the cells for 12 h.
Immunoblotting analysis
HCAECs were grown in six-well plates at approximately 60–70% confluence for 24 h and then
treated with aspirin at indicated concentrations or times. The cells were harvested and subjected
to immunoblotting analysis. Immunoblotting was performed in accordance with our previously
described method [18]. In brief, equal amounts of total protein were separated using 8% or 12%
SDS-PAGE and transferred to PVDF membranes (Millipore, USA). The membranes were
blocked in 5% nonfat milk (Bio-Rad Laboratories, USA) for 1 h and then incubated with pri-
mary antibodies overnight at 4 8C. Goat anti-rabbit or anti-mouse IgG conjugated with HRP
(1:5,000; Jackson ImmunoResearch, USA) served as secondary antibodies. Finally, immunore-
active bands were detected via the exposure method. The antibodies used in this study were as
follows: LC3B (1 mg/mL, #L7543; Sigma-Aldrich, USA), p-eNOS (1:1,000, #9571s; Cell Signaling
Technology, USA), eNOS (1:1,000, #9572s; Cell Signaling Technology, USA), GAPDH (1:2,000,
#2118L; Cell Signaling Technology, USA), phosphor-NF-kB (p-NF-kB, 1:1,000, #3033s; Cell
Signaling Technology, USA), p62 (1:1,000, #5114; Cell Signaling Technology, USA), Beclin-1
(1:1,000, #3495s; Cell Signaling Technology, USA), and p-p38 mitogen-activated protein kinase
(1:1,000, #4511s; Cell Signaling Technology, USA).
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NO measurement
NO levels were detected by Griess reaction on the basis of the total concentrations of NO stable
end products, namely, nitrite and nitrate. Following the manufacturer’s instructions of a
commercial NO assay kit (Beyotime Institute of Biotechnology, Shanghai, China), the culture
medium from cultures subjected to different treatments was collected, and 50 mL of culture
medium, 50 mL of Griess reagent I, and 50 mL of Griess reagent II were added to each well of 96-
well plates at room temperature for 2 min, as previously described [19, 20] (PMID: 28413519).
Then, the optical density (OD) of the 96-well plates was measured at 540 nm on a plate reader
(Epoch Microplate Spectrophotometer, Bio Tek, USA). NO production was then calculated by
comparing the OD values of the samples with the standard curve.
ELISA assay
Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion mole-
cule-1 (sVCAM-1) levels in the culture media after different treatments were measured using
commercially available ELISA kits (Dakewei Biotech, Shenzhen, China). Following the manu-
facturer’s instructions, the culture media were centrifuged at 2,000 rpm for 15 min at 4 8C to
remove cell debris. The plates were mixed with biotinylated antibody working solution (1:50, 50
mL/well) specific for sICAM-1 for 1 h. The plates were incubated with biotinylated antibody
working solution (1:100, 100 mL/well) specific for sVCAM-1 for 2 h after they were incubated for
2 h with the standards and samples and washed. The plates washed with 13 washing buffer
(three times, 1 min/time) were incubated with streptavidin-HRP working solution (100 mL/well)
for 20 min. Subsequently, the plates were washed with 13 washing buffer (three times, 1 min/
time) and added with 100 mL/well TMB substrate solution in the dark for 10–15 min. The
enzyme-substrate reaction was stopped by quickly pipetting 100 mL of the stop solution into
each well. OD values were measured at 450 nm on a plate reader, and the results were calculated
by comparing the standards with the blanks. The medium concentration was calculated as per
microgram of cell protein in each well.
Monitoring autophagic flux using tandem mRFP-GFP-tagged LC3
HCAECs were grown in 12-well plates to approximately 80% confluence and then infected with
adenovirus harboring tandem fluorescent mRFP-GFP-LC3 (HanBio, Shanghai, China) for 24 h.
The cells were treated with or without 2.5 mM aspirin or 100 nM rapamycin (Sangon Biotech,
Shanghai, China) for 16 h, and the green and red fluorescence was analyzed via fluorescence
microscopy. The number of autophagosomes (dots in yellow in merged images) and autoly-
sosomes (dots in red only and not in green) in images was visually counted in five randomly
selected fields per group. Images were analyzed using Image J.
Small interfering RNA
Beclin-1 small interfering RNA (siRNA) and negative control (NC) siRNA were synthesized by
GenePharma (Suzhou, China), the sequences of which were as follows:
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HCAECs were seeded in six-well plates and grown to 70–80% confluence. The cells were
transfected with NC siRNA (50 nM) or Beclin-1 siRNA (50 nM) by using Lipofectamine 3000
(Thermo Fisher Scientific, Inc., USA) according to the manufacturer’s instructions. After 48 h of
transfection, the cells were treated with or without 2.5 mM aspirin for 16 h.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 software (SPSS, Inc., USA) and GraphPad
Prism 6 software (GraphPad Software, USA). Data from at least three independent experiments
were presented as the mean ± standard deviation. Different treatment groups were compared
using Student’s t-test or ANOVA when appropriate. Statistical significance was considered at
P < 0.05.
RESULTS
Aspirin increased eNOS activity in a dose-dependent manner
To determine the effects of aspirin on HCAEC functions, we detected the levels of p-eNOS
protein expression and NO. Results showed that p-eNOS (Fig. 1A) and NO levels (Fig. 1B)
increased in a dose-dependent manner under aspirin treatment compared with control values,
indicating that aspirin enhanced eNOS activity in ECs.
Aspirin protected ECs against ox-LDL, Ang-II, and HG injuries
To determine whether aspirin reduces EC damage caused by ox-LDL, Ang-II, and HG, we
detected the expression levels of p-p38, p-NF-kB, sICAM-1, and sVCAM-1. Results showed that
50 mg/mL ox-LDL, 1 mM Ang-II, and 25 mM HG substantially increased p-p38 and p-NF-kB
protein expression levels in the HCAECs, and aspirin reduced p-p38 and p-NF-kB protein
expression levels (Fig. 2A). ox-LDL, Ang-II, and HG also remarkably increased sICAM-1 and
sVCAM-1 expression levels in the HCAECs, but aspirin reduced sICAM-1 and sVCAM-1
expression levels (Fig. 2B).
NC siRNA Forward: 59-UUCUCCGAACGUGUCACGUTT-39
Reverse: 59-ACGUGACACGUUCGGAGAATT-39
Beclin-1 siRNA #1 Forward: 59-UCGCUGAAGACAGAGCGAUTT-39
Reverse: 59-AUCGCUCUGUCUUCAGCGATT-39
Beclin-1 siRNA #2 Forward: 59-AGUUGGAUAAUGUGGGAAATT-39
Reverse: 59-UUUCCCACAUUAUCCAACUTT-39
Beclin-1 siRNA #3 Forward: 59-GAGACAUUAUGGAGAGAUUTT-39
Reverse: 59-AAUCUCUCCAUAAUGUCUCTT-39
Beclin-1 siRNA #4 Forward: 59-CAGUUUGGCACAAUCAAUATT-39,
Reverse: 59-UAUUGAUUGUGCCAAACUGTT-39
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Aspirin triggered EC autophagy
We explored the underlying mechanisms by which aspirin protects vascular ECs from damage
induced by ox-LDL, Ang-II, and HG. Results showed that 0.63, 1.25, and 2.5 mM aspirin
increased the LC3II/LC3I ratio but reduced p62 expression in the HCAECs in a dose-dependent
Fig. 1. Aspirin increased p-eNOS level and NO concentration in the HCAECs. HCAECs were incubated
with aspirin at various concentrations (0, 0.315, 0.63, 1.25, 2.5, and 5 mM) for 16 h. Cell lysates were
subjected to immunoblotting assay with antibodies against p-eNOS, eNOS, and GAPDH. (A) The left panel
shows the representative data. The right panel presents the band quantification of three experiments. (B)
Cell lysates were subjected to Griess reagent to determine NO levels. Each bar represents the mean ± SD
calculated from three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001: aspirin treatment
was compared with the control
Fig. 2. Aspirin reduced injury to HCAECs caused by ox-LDL, Ang-II, and HG. (A) HCAECs were incu-
bated with 2.5 mM aspirin, 50 mg/mL ox-LDL, 1 mM Ang-II, and 25 mM HG for 12 h. Cell lysates were
subjected to immunoblotting assay with antibodies against p-P38, p-NF-kB, and GAPDH. The upper panel
shows the representative data. The lower panel presents the band quantification of three experiments. (B)
ELISA was performed to determine (I) sICAM-1 and (II) sVCAM-1 expression levels in the HCAEC
culture media. Each bar represents the mean ± SD from three independent experiments. **P < 0.01 and
***P < 0.001 versus control; ##P < 0.01 and ###P < 0.001 versus aspirin treatment
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manner (Fig. 3A), indicating induction of autophagy. Autophagic flux, which was tracked using
Ad-RFP-GFP-LC3, revealed that aspirin substantially enhanced the quantities of autophago-
somes (yellow puncta) and autolysosomes (red puncta). This outcome was similar to the effects
of rapamycin (Fig. 3B). Rapamycin, which is a pharmacological activator of autophagy, was used
as a positive control. These data indicated that aspirin induces EC autophagy.
Effects of Beclin-1 knockdown on aspirin-induced EC protection
Beclin-1 primarily functions as a scaffolding protein to promote the formation of the Beclin-1/
Vps34 complex, which accelerates the autophagy cascade [18]. Therefore, we assessed the role of
Beclin-1 in aspirin-induced HCAEC autophagy and protection. After Beclin-1 was successfully
knocked down (Fig. 4A), aspirin treatment suppressed the increase in the LC3II/LC3I ratio and
p-eNOS and NO levels but suppressed the decrease in p-p38, p-NF-kB, and p62 levels compared
with those of NC (Fig. 4B and C). Moreover, sICAM-1 and sVCAM-1 levels increased after
Fig. 3. Aspirin induced autophagy in the HCAECs. (A) HCAECs were incubated with aspirin at various
concentrations (0, 0.315, 0.63, 1.25, 2.5, and 5 mM) for 16 h. Cell lysates were subjected to immuno-
blotting assay with antibodies against LC3, p62, and GAPDH. The left panel shows the representative
data. The right panel presents the band quantification of three experiments. Each bar represents the
mean ± SD calculated from three independent experiments. *P < 0.05 and **P < 0.01; aspirin treatment
was compared with the control. (B) Autophagosomes and autolysosomes were tracked using mRFP-GFP-
LC3. HCAECs were infected with mRFP-GFP-LC3 at 50 MOI for 24 h, treated with or without aspirin (5
mM) or rapamycin (100 nM) for 16 h, and analyzed via fluorescence microscopy. Autophagic flux was
determined by counting autophagosomes (yellow puncta) and autolysosomes (red puncta) in the merged
images. The green puncta represent GFP, the weakening of which can indicate the fusion of lysosomes
and autophagosomes to form autolysosomes. (I) GFP of control. (II) RFP of control. (III) Merge of
control. (IV) GFP of aspirin. (V) RFP of aspirin. (VI) Merge of aspirin. (VII) GFP of rapamycin. (VIII)
RFP of rapamycin. (IX) Merge of rapamycin. Each bar represents the mean ± SD calculated from three
independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control; #P < 0.05 and ##P < 0.01
versus control
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Beclin-1 knockdown (Fig. 4D). These results suggested that aspirin-induced HCAEC autophagy
and protection are dependent on Beclin-1.
DISCUSSION
The present study revealed that aspirin increased eNOS level and endogenous NO in the
HCAECs under ox-LDL-, Ang-II-, and HG-induced injury by suppressing p38 and NF-kB
phosphorylation. Aspirin also decreased the expression levels of adhesion molecules (i.e.,
sICAM-1 and sVCAM-1). Beclin-1 was required for aspirin-induced autophagy to
ameliorate endothelial dysfunction in the HCAECs. Therefore, aspirin protects HCAECs
from ox-LDL-, Ang II-, and HG-induced injury in an autophagy-dependent manner, a
Fig. 4. Protective effects of aspirin were dependent on Beclin-1 in the HCAECs. (A) Beclin-1 protein
expression was detected by immunoblotting assay in the HCAECs. Cells were transfected with 50 nM NC
siRNA or 50 nM Beclin-1 siRNA. (B) HCAECs were transfected with siRNA for 48 h and then treated with
or without 2.5 mM aspirin for an additional 16 h. Cell lysates were subjected to immunoblotting assay with
antibodies against LC3, p62, p-eNOS, eNOS, p38, and p-NF-kB or GAPDH. (C and D) Cell lysates were
subjected to Griess reagent to measure NO levels and subjected to ELISA to determine (I) sICAM-1 and
(II) sVCAM-1 expression levels. Experiments were replicated at least three times. Bars represent the mean
± SD. *P < 0.05, **P < 0.01, and ***P < 0.001: aspirin treatment versus control; #P < 0.05: Beclin-1 siRNA
versus NC siRNA. NC: negative control
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process that increases eNOS expression and decreases the P38 MPAK and NF-kB signaling
pathways (Fig. 5).
Vascular ECs can secrete various cytokines, such as NO, prostacyclin, endothelin-1, and von
Willebrand factor, which are involved in regulating vascular tone, cell adhesion, smooth muscle
cell proliferation, vascular inflammation and angiogenesis, and remodeling processes [1, 21]. As
a signaling mediator, NO has diverse biological activities. Impaired NO bioavailability promotes
endothelial dysfunction, a fundamental pathophysiological mechanism in the progression of
cardiovascular and cerebrovascular diseases. Endothelial dysfunction participates in the devel-
opment of various diseases, such as hypertension, atherosclerosis, coronary heart diseases, and
diabetes. In the vasculature, NO is biosynthesized through eNOS catalytic activity. The results of
the present study indicated that phosphorylated eNOS and total eNOS expression levels
increased after treatment with aspirin in a dose-dependent manner. Decreased eNOS activity is
the most important marker of EC dysfunction that results in impaired bioavailability of
endogenous NO. Aspirin increased NO production in a dose-dependent manner. Evidence from
explorative clinical trials suggests that treatment with low aspirin dose can help maintain
vascular homeostasis by improving endothelium-dependent arterial relaxation [22]. The present
study found that aspirin increased p-eNOS level and NO release in a dose-dependent manner, a
result similar to that of a previous research [11].
Aspirin reduces the onset of cardiovascular diseases and inhibits inflammation and certain
cancers. The NF-kB and MAPK signaling pathways play important roles in the formation and
development of atherosclerosis [23], hypertension [24], and diabetes [25, 26]. Ang-II can pro-
mote the formation of atherosclerosis by activating the NF-kB and MAPK signal transduction
pathways. Ang-II induces hypertensive endothelial injury in human umbilical vein ECs
(HUVECs) via the Nrf2/NF-kB pathways [24]. Animal studies have demonstrated that ox-LDL
is involved in foam cell formation and aggravates atherosclerosis through the NF-kB and p38
MAPK signal transduction pathways. Jayakumar et al. found that HG induces CAM expression
and NF-kB activation in HUVECs [26]. In the present study, the HCAECs were pretreated with
aspirin for 30 min and then cocultured with 50 mg/mL ox-LDL, 1 mM Ang-II, and 25 mM HG
Fig. 5. Schematic of role of aspirin in the HCAECs. Aspirin protects HCAECs from ox-LDL-, Ang-II-, and
HG-induced injury in an autophagy-dependent manner
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for 24 h. Aspirin substantially inhibited the ox-LDL-, Ang II-, and HG-induced p38 and NF-kB
activation in the HCAECs. Meanwhile, aspirin remarkably decreased the secretion of sICAM-1
and sVCAM-1, which were augmented by ox-LDL, Ang-II, and HG stimulation in the HCAECs.
Results suggested that aspirin protects EC functions in ox-LDL-, Ang II-, and HG-induced cell
injury.
Autophagy provides cellular metabolic precursors, especially in response to starvation, by
degrading cellular components by lysosomes. Aspirin features an autophagic effect by activating
the AMPK pathway and inhibiting mTOR signaling [27] or the p38/reactive oxygen species
pathway in tumor cell lines [28] and heart fibrosis [29]. Nevertheless, the autophagic effects of
aspirin on ECs have not been investigated yet. The LC3 II/I ratio was used as an indicator of
autophagy–mitophagy flux. In autophagy, autophagosome degradation by lysosomes decreases
SQSTM1/p62 levels. In the present study, aspirin increased the LC3II/LC3I ratio in the HCAECs
in a dose-dependent manner. However, p62 expression gradually decreased, and the number of
autophagosomes and autolysosomes substantially increased after 2.5 mM aspirin treatment
compared with the control. These data indicated that aspirin induces autophagy in ECs.
Beclin-1 plays an important role in the formation of autophagosomes and regulates auto-
phagy [30]. In HUVECs, autophagy activation prevents cell death upon exposure to oxidative
stress by activating Beclin-1 [31]. Beclin-1 knockdown inhibits autophagy and survival in ox-
LDL-treated HUVECs [32]. In the present study, Beclin-1 knockdown reduced the autophagic
and endothelial protective effects of aspirin in the HCAECs. In addition, Beclin-1 knockdown in
the HCAECs increased p38 MAPK phosphorylation and the NF-kB signaling pathway with
aspirin treatment. Meanwhile, sICAM-1 and sVCAM-1 contents increased. Therefore, Beclin-1
is required for aspirin-induced autophagy to protect EC functions.
CONCLUSIONS
Aspirin can ameliorate EC dysfunction induced by ox-LDL, Ang-II, and HG by activating
autophagy in a Beclin-1-dependent manner. The results provide additional experimental evi-
dence and scientific rationale for aspirin treatment of cardiovascular diseases.
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